Weight-loss drug 'could be profitably made for as little as €4.40 a month'  

Ozempic maker Novo Nordisk currently charges almost €925 for a month's supply in the US

'Profit margin is immense,' on drugs like Ozempic, said Melissa Barber, a public health economist at Yale and the study’s corresponding author.

Ozempic could be profitably produced for less than $5 a month, even as maker Novo Nordisk charges almost $1,000 (€925) in the US, according to a study that revives questions about prices for top-selling treatments for diabetes and obesity.

The blockbuster drug could be manufactured for 89 cents to $4.73 (€4.40) for a month’s supply, figures that include a profit margin, researchers at Yale University, King’s College Hospital in London and Doctors Without Borders reported in the journal JAMA Network Open.